Befejeződött3. fázis
Efficacy and safety of the proposed biosimilar PERT-IJS versus EU-Perjeta® along with trastuzumab and chemotherapy (carboplatin and docetaxel) as neoadjuvant treatment in chemotherapy naïve patients with early stage or locally advanced HR negative and HER2 positive breast cancer
Key facts
- Where
- Biala Podlaska, Cracow, Lodz, Rzeszów és Warsaw, LengyelországSee the 7 sites
- Phase
- 3. fázis
Where in Lengyelország
- Wojewodzki Szpital Specjalistyczny W Bialej PodlaskiejBiala Podlaska, LengyelországNo longer taking part
- Pratia S.A.Cracow, LengyelországNo longer taking part
- Szpital Specjalistyczny Im. Ludwika Rydygiera W Krakowie Sp. z o.o.Cracow, LengyelországNo longer taking part
- Centra Medyczne Medyceusz Sp. z o.o.Lodz, LengyelországNo longer taking part
- Instytut MSF Sp. z o.o.Lodz, LengyelországNo longer taking part
- Mruk-Med I Sp. z o.o.Rzeszów, LengyelországNo longer taking part
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyWarsaw, LengyelországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Biocon Biologics UK Limited
- Trial code
- EU 2023-506163-34-00
- Record updated
- 2023. november 27.